Literature DB >> 428185

Kinetics and absolute bioavailability of atenolol.

W D Mason, N Winer, G Kochak, I Cohen, R Bell.   

Abstract

Twelve healthy volunteers received four single doses of atenolol (25-, 50-, and 100-mg oral solutions and a 50-mg intravenous infusion), each dose separated by at least one week. Blood and urine assayed for atenolol by a high pressure liquid chromatography (HPLC) method. Kinetic analysis of the intravenous data indicates a three-compartment model with elimination from the central compartment. The mean (+/- SD) terminal elimination half-life is 6.06 +/- 2.02 hr, the mean volume of the central compartment is 0.173 L/kg, and 94.1 +/- 8.0% of the intravenous dose is excreted in the urine. The mean value of the plasma clearance is 10.7 +/- 1.27 L/hr and of the renal plasma clearance, 10.4 +/- 1.14 L/hr. The mean absolute bioavailability for the 25-, 50-, and 100-mg oral doses is 0.52 +/- 0.18, 0.54 +/- 0.12, and 0.58 +/- 0.16, respectively. The maximum plasma concentration varies as a linear function of dose. Time to mean maximum plasma concentration (3.0 hr) and the time for half of the bioavailable dose to be absorbed (2.0 hr) do not differ significantly with dose. The mean renal plasma clearance after oral doses (9.49 +/- 1.6 L/hr) is in the same range as renal clearance after intravenous doses.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 428185     DOI: 10.1002/cpt1979254408

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  The combination of slow-release nifedipine and atenolol for stable angina.

Authors:  D G Waller; V F Challenor
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

4.  Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.

Authors:  Sheila Annie Peters
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Perturbation of upper gastrointestinal transit and antroduodenal motility by experimentally applied stress: the role of beta-adrenoreceptor mediated pathways.

Authors:  J D O'Brien; D G Thompson; S J Day; W R Burnham; E Walker
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

Review 6.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

7.  A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models.

Authors:  Megerle L Scherholz; James Forder; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-08       Impact factor: 2.745

Review 8.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

9.  Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.

Authors:  Yukiko Metsugi; Yoshihiro Miyaji; Ken-ichi Ogawara; Kazutaka Higaki; Toshikiro Kimura
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

10.  Atenolol elimination in the neonate.

Authors:  P C Rubin; L Butters; B Reynolds; J Evans; D Sumner; R A Low; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.